Cargando…
Steroid treatment in the management of destructive thyrotoxicosis induced by PD1 blockade
OBJECTIVE: Destructive thyroiditis is the most common endocrine immune-related adverse event (iRAEs) in patients treated with anti-PD1/PD-L1 agents. Given its self-limited course, current guidelines recommend no treatment for this iRAE. Nevertheless, in patients with enlarged thyroid volume and a po...
Autores principales: | Brancatella, Alessandro, Pierotti, Laura, Viola, Nicola, Lupi, Isabella, Montanelli, Lucia, Cremolini, Chiara, Piaggi, Paolo, Chella, Antonio, Antonuzzo, Andrea, Sgrò, Daniele, Antonangeli, Lucia, Sardella, Chiara, Brogioni, Sandra, Marcocci, Claudio, Santini, Ferruccio, Latrofa, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254312/ https://www.ncbi.nlm.nih.gov/pubmed/35622442 http://dx.doi.org/10.1530/ETJ-22-0030 |
Ejemplares similares
-
OR11-3 Steroid Treatment in the Management of Destructive Thyrotoxicosis Induced by PD1 Blockade
por: Antonangeli, Lucia, et al.
Publicado: (2022) -
Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021) -
Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021) -
Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases
por: Lupi, Isabella, et al.
Publicado: (2019) -
Subacute Thyroiditis During the SARS-CoV-2 Pandemic
por: Brancatella, Alessandro, et al.
Publicado: (2021)